Purpose Multiple endocrine neoplasia type 1 (MEN1) is caused by germline inactivating mutations of the MEN1 gene. Currently, no direct genotype-phenotype correlation is identified. We aim to analyze MEN1 mutation site and features, and possible correlations between the mutation type and/or the affected menin functional domain and clinical presentation in patients from the Italian multicenter MEN1 database, one of the largest worldwide MEN1 mutation series published to date. Methods The study included the analysis of MEN1 mutation profile in 410 MEN1 patients [370 familial cases from 123 different pedigrees (48 still asymptomatic at the time of this study) and 40 single cases].
Introduction
Multiple endocrine neoplasia type 1 (MEN1; MIM#131100) is an inherited rare endocrine tumor syndrome, affecting primarily the parathyroids, the anterior pituitary, and the neuroendocrine tissues of the gastroentero-pancreatic (GEP) and thoracic tracts. MEN1 patients can develop varying combinations of more than 20 endocrine and non-endocrine tumors and lesions, presenting highly variable spectra of clinical manifestations even among members of the same family and identical twins. The responsible gene, the tumor suppressor MEN1, was identified in 1997 at 11q13.1 locus (OMIM gene/locus number 613,733), and it consists of 10 exons encoding a 610 amino acid nuclear protein, named menin. Germline inactivating mutations of the MEN1 gene are responsible for the development of the syndrome. MEN1 is an autosomal dominant syndrome that can be inherited from the affected parent (familial form; over 90% of all reported cases) or, more rarely, occurs as a consequence of an embryonic de novo heterozygote MEN1 mutation (non-familial form; accounting for less than 10% of cases) [1] . MEN1 mutations are identified in 80-90% of probands with familial disease, and in a smaller percentage of simplex cases. To date, over 1500 germinal and somatic mutations of the MEN1 gene have been identified in familial and single cases [2, 3] .
Mutation analysis of the MEN1 gene can confirm the clinical diagnosis of the index case, and allow the early identification of asymptomatic mutation carriers, years before a MEN1-associated hormonal abnormality and/or tumor mass can be detected [2, 4] . During the last two decades, an increasingly frequent application of the genetic test has forwarded the diagnosis of the disease, allowing an early tumor-surveillance screening program of mutation carriers, and granting the reduction of syndrome-derived morbidity and mortality. Unfortunately, as reported by most worldwide epidemiology studies, a clear, direct genotype-phenotype correlation has not been identified, strongly reducing the possibility to foresee the exact future clinical manifestations associated with a specific gene mutation or protein mutated region [2, [5] [6] [7] . Recently, two studies by the "Groupe d'étude des tumors endocrines (GTE)" reported a trend for intra-familial correlation of the disease's clinical presentation and severity, and heritability of some MEN1 tumors, but without any direct genotype-phenotype correlation [8, 9] . The first study reported a two-fold increased risk of death in patients bearing a MEN1 mutation affecting menin domain interacting with the transcription factor JunD [8] . The second evidenced a positive intra-familial heritability, but only for three specific MEN1-associated tumor types, namely pituitary adenomas, adrenal tumors, and thymic tumors [9] . However, this appears to be only as a minor intra-familial correlation that progressively decreases with the degree of the genetic relationship, suggesting, together with the absence of a direct genotype-phenotype correlation, the existence of other possible modifying genetic and epigenetic factors influencing MEN1 clinical phenotypes.
In this study, we described the MEN1 mutation profile in 410 MEN1 patients [a total of 370 familial cases from 123 different pedigrees (of which 48 were still non-presenting any biochemical or imaging sign of tumors or any symptoms of MEN1 at the time of this study) and 40 single cases], collected through the Italian multicenter MEN1 patient database [10] , one of the largest worldwide MEN1 mutation series published to date. We described and analyzed the main characteristics of identified MEN1 mutations and investigated possible direct correlations between the mutation type and/or the affected menin functional domain and the disease clinical presentation.
Materials and methods

Patients
Patients were, retrospectively and prospectively, collected in the "Italian MEN1 Database" [10] from 2011 to May 2017 (retrospective data included in the database were derived from the Italian Registry of Multiple Endocrine Neoplasia (RINEM), originally created in 1991), along with their birth date, gender, personal and familial clinical history, first MEN1-manifestation (type and age of onset), age at MEN1 genetic and/or clinic diagnosis, all MEN1-associated endocrine and non-endocrine lesions, all MEN1-related surgical and medical treatments and the result of the MEN1 genetic test. The Italian MEN1 database includes data from 14 different endocrine main referral centers located in 12 cities from 9 different Italian regions, covering the entire national territory [10] . This study selected a total of 410 MEN1 patients with an identified MEN1 gene mutation (176 men and 234 women; aged 1-76 years at the time of MEN1 diagnosis). MEN1 patients without an identified MEN1 mutation were excluded from the present study.
Selected patients consisted of 370 familial cases, from 123 different pedigrees, and 40 single cases. Forty-eight subjects, one single case and 47 familial cases from 28 pedigrees, were still without any biochemical or imaging sign of tumors or any symptoms of MEN1 at the time of this study (mean age 25.9 ± 16.0 years; range 5-75 years). They were diagnosed as MEN1 only by the genetic test (mean age 19.3 ± 15.8 years; range 1-75 years). They are included, in this study, as asymptomatic, and considered only for the analysis of the distribution and features of MEN1 mutations, but not for the study about genotype-phenotype associations.
This study was initially approved by the Internal Review Board of the University of Florence (coordinating center) and then by the local ethics committee of each of the participating centers. All patients gave informed consent for genetic analyses. Data collected were made appropriately anonymous and each patient was identified, during this study, by a unique alphanumeric identification code; data were also analyzed as aggregates.
MEN1 gene mutation analysis
Mutational analysis of the MEN1 gene had been previously performed in all MEN1 patients included in the database. Mutation screening included the PCR-based Sanger's sequencing analysis of the coding region (exons 2-10) and the exon-intron junctions (splicing sites) of the MEN1 gene (this test usually fails in detecting a MEN1 in about 10-15% of affected individuals, not covering promoter and untranslated regions and not being able to identify large intragenic deletions/insertions) [11] . Obtained sequences were compared to the wild type reference sequence of the MEN1 gene (OMIM 613733); mutations were classified using the standard nomenclature for the description of human DNA sequence variants. Benign MEN1 polymorphisms [2] were distinguished from mutations, during sequencing analysis, for genetic diagnosis. Nonsynonymous missense mutations have been considered as pathogenic if: (1) they were previously reported as associated with the development of the syndrome in MEN1 pedigrees, in published literature; (2) they were reported as pathogenic variations in mutation databases (i.e., Human Mutation Database, OMIM, etc); (3) they were novel but showed to segregate with the development of MEN1 within our pedigree/s. Exon-intron junction mutations were considered as pathological if they have been previously described in literature or reported in mutation databases as associated with the development of the syndrome. If novel, they were analyzed by specific in silico prediction tools of splicing site analysis (i.e., Human Splicing Finder Version 2.4.1 at http://www.umd.be/HSF/). One non-familial case was found with the IVS5 + 27 C > T variation in exon 5; in silico analysis failed to find any alteration of the splicing sites and no relatives were available for the analysis of disease co-segregation with genotype. She was considered as non-carrier of a pathogenic MEN1 mutation and excluded from this study.
When a MEN1 mutation was detected, the mutation screening was extended to first-degree relatives, independently of the presence of specific MEN1-related signs and symptoms. Four MEN1 pedigrees were analyzed by multiplex ligation-dependent probe amplification (MPLA), a probe-based method for the detection of gene copy number change and gross intra-genic deletions, insertions or rearrangements, after they resulted negative for MEN1 mutation by the sequencing analysis.
Fifteen clinically affected MEN1 patients [4.0% of all the, genetically screened, affected patients (377); 6 familial cases from 3 pedigrees and 9 non-familial cases] resulted to be negative to the sequencing analysis of the MEN1 gene. MPLA has not yet been performed, at the time of this study, in all these patients. Four MEN1-negative non-familial cases were analyzed for mutation of the CDKN1B gene and they all resulted to be negative.
No additional multigene panel screening was performed in all our patients, to date.
Data analysis
Mutation distribution and classification were analyzed by descriptive statistics; data are presented as nominal categories and percentages.
Correlation between age of onset of the first clinical manifestation and mutation type and/or mutated gene region was analyzed by Student's t-test, assuming a positive significance with p < 0.05 (only groups of mutations including more than 20 patients were included in the analyses).
Correlations between clinical data and mutation type and/or mutated gene region were analyzed by chi-squared test, assuming a positive significance with p < 0.05 (Yates' correction was applied for clinical categories with less than five cases).
Results
Sequencing analysis of the MEN1 gene identified 95 different inactivating mutations located in the coding region and splicing sites of the gene; MPLA analysis identified four large intra-genic deletions within the MEN1 gene, all of them including more than one exon. Non-truncating mutations include missense and in-frame deletions c Four patients bear one mutation in exon 4 and one mutation in exon 8 Agarwal [21] In-frame deletion Giacché [30] In-frame deletion Fig. 1) .
A common founder effect has not been identified (by reconstructing family history) for any of the families and/or non-familial cases bearing the same mutation.
We identified a MEN1 index case and four of her firstdegree relatives (father, sister, and two of the sister's sons) as carriers of two different inactivating MEN1 mutations, one in exon 4 (Leu249Pro missense mutation) and one in exon 8 (g.1181delC frameshift mutation). The genetic analysis of index case's parents identified the father as carrier of both the MEN1 mutations, while the mother resulted to be wild type for the MEN1 gene; both the mutations are located on the same MEN1 allele, and inherited from the father. The double mutated index case and three mutated first-degree relatives (father, sister, and one of the sister's sons) are clinically affected, with first clinical manifestation appearing at 17, 60, 14, and 15 years, respectively, and all presenting a combination of primary hyperparathyroidism (PHPT) and active prolactinoma (PRLoma). The sister's mutated younger son (aged 13) was still asymptomatic at the time of the study.
Classification and main features of all identified MEN1 mutations, as well as their distribution in our familial and non-familial patients, are reported, in detail, in Table 2 . The distribution of MEN1-associated tumors, in our series of patients, is depicted in Tables 3 and 4 , based on the MEN1 mutation type or the MEN1 mutated region, respectively.
No statistical correlation was found between disease age of onset and MEN1 mutation type or localization (Table 5) . No differences were found in the distribution of PHPT and pituitary tumors between different MEN1 mutation types and localization. Statistical analyses evidenced a significantly higher percentage of GEP neuroendocrine tumors (GEP-NETs) in MEN1 clinically affected patients bearing a nonsense mutation (72.46%) with respect to frameshift mutations (51.85%; χ 2 = 8.44, p = 0.004) and missense mutations (54.32%; χ 2 = 5.24, p = 0.022). Also a significantly higher percentage of thoracic neuroendocrine tumors (NETs), previously referred as thoracic carcinoids, was reported in MEN1 clinically affected patients bearing a splicing-site mutation (18.42%) with respect to frameshift mutations (5.6%; χ 2 = 6.92, p = 0.009). Conversely, no statistical association was found in the occurrence of the MEN1 main endocrine tumors, and in the number of different endocrine tumors per patient, between patients bearing a truncating mutation and patient with a nontruncating mutation (Table 6) .
Nineteen patients (4.63%) died because of MEN1-related causes and malignant progression of MEN1 tumors. Thirteen died because of malignant gastrinomas [7 In-frame inser ons/del ns 4%
Large intragenic del ns 4% Fig. 1 Comparison of distribution of MEN1 mutation types in our series of patients with respect to published data [2, 3] These numbers included also the same 4 affected patients bearing two different mutations (a frameshit and a missense) Table 4 MEN1-associated tumor distribution, in our series of patients, based on the MEN1 2 because of kidney failure (due to an undiagnosed hypercalcemic hyperparathyroidism), 2 because of post-surgical complications of a macro PRLoma resection (one from severe pituitary insufficiency and one from post-surgical hyponatremia), and 2 because of cardiac complications due to electrolyte imbalance (cardiac arrest from ventricular fibrillation with hypokalemia). The average age at death was 59.1 years ± 14.5 (range 36-84 years). The average age at the first clinical manifestation was 43.1 ± 17.4 years (range 17-75 years), and the average age at diagnosis of MEN1 was 55.8 ± 15.2 years (range 33-80 years). There was no association between MEN1-related premature death, cause of death, and death age with the MEN1 mutation type or localization.
Discussion
Our study analyzed a large series of 410 MEN1-mutated patients, bearing 95 different inactivating mutations and 4 gross intra-genic deletions. Analysis of mutation type and distribution were similar to data previously published for MEN1 syndrome [2, 3] , identifying mutations (i.e., frameshift and nonsense mutations) that generate a truncated menin protein, unable to translate to the nucleus, as the most frequent mutations (54.5%) (Fig. 1) . Frameshift mutations were confirmed to be the most common MEN1 mutations, accounting alone for over 41% of all identified variations. Nonsense mutations were prevalently located in exon 10 (6 of 13), while exon 9 resulted to be the principal exon affected by missense mutations (7 of 26) ( Table 1) . No specific mutational hot spots were identified, even though we confirmed that exons 2, 9, and 10 were the three most mutated exons [2, 3] ; in particular, a high concentration of insertion and deletion points was detected in exons 2 and 10, and they were presumably associated with short nucleotide repeats within these two exons.
No correlation was found between disease age of onset, distribution of PHPT and pituitary tumors and the MEN1 mutation type or localization. We found that patients affected by GEP-NETs had a significantly higher frequency of nonsense than frameshift or missense mutations and that the presence of a thoracic NETs was significantly more common in patients bearing a splicing-site mutation with respect to those presenting a frameshift mutation. These findings could open interesting perspectives for prediction and prognosis, but further studies, including broad and different MEN1 populations, are needed to confirm a real increased risk/predisposition to develop GEP-NETs or thoracic NETs to carriers of nonsense or splicing-site mutations, respectively, and to exclude that they can be only accidental statistical associations. No selection biases can be suspected in the collection of our MEN1 patients, since they were obtained from 14 major referral centers for endocrine inherited tumors and MEN syndromes, which constantly visit and follow up MEN1 patients from all the 20 different Italian Regions. This multi-centric patients' collection grants to cover all the three main geographical areas of Italy (North, Center, South) and, thus, to obtain a large group of MEN1 patients who are representative of all affected individuals in Italy.
Despite these positive statistical associations, the detailed analysis of intra-familial clinical phenotypes, in all our 23 pedigrees, showed a high variability in disease age of onset and severity of the clinical manifestations, even in the presence of the same mutation, confirming the absence of a direct genotype-phenotype correlation. Recently, also another study failed to find a significant direct correlation between the type and location of MEN1 mutations and clinical phenotypes in 54 MEN1 patients with Italian ancestry [12] . Our series of patients also included a pair of monozygous twins; at the time of the study (age under 35 years), they manifested PHPT only, being inconclusive for the study of genotype-phenotype correlation. A future clinical follow-up of these twin sisters would be very useful to evaluate the role of epigenetic or extrinsic factors in MEN1 tumorigenesis.
We reported a large MEN1 family (24 mutated members, of which 4 still asymptomatic at the time of this study), bearing the frameshift g.1449_1459 del11 in exon 9 (Table  2) , presenting highly variable intra-familial disease phenotypes and varying onset of MEN1 manifestations. This family presented a relatively high mean age of MEN1 onset (mean age of first clinical manifestation 47.8 ± 15.2 years; median age of first clinical manifestation 51.5 years) with 50% of members developing the disease by the age of 52. Curiously, three members of this family did not develop PHPT at the age of 55, 57 and 64 years, respectively; but had a common involvement of the neuroendocrine tissues of the GEP tract (two with duodenal gastrinomas associated with Zollinger Ellison syndrome and one with nonfunctioning pancreatic NET).
We also identified a family with five members bearing one allele with two different mutations (Leu249Pro in exon 4 and g.1181delC in exon 8). The presence of a double mutation does not influence the severity of the disease in this pedigree, with respect to the other MEN1 families bearing a single mutation. Interestingly, this pedigree presented three members (the MEN1 index case, her sister and her sister's son) with a very early age of onset of the first MEN1 clinical manifestation (17, 15 , and 14 years, respectively), with PRLoma being the first clinical sign in all of them. Conversely, the father of the index case presented PHPT as the first clinical sign of MEN1, at a later age of onset (60 years). This onset anticipation and pituitary first involvement, in the second and third generations, led us to suspect the presence of other influencing genetic factors (presumably inherited from maternal line by the index case and her sister). Another family, bearing a single, different, MEN1 mutation (g.1364delC, in exon 9) showed a similar disease presentation to the family described above, with the pedigree MEN1 index case (father) presenting the first clinical manifestation, PHPT, at the age of 47 years, while his two daughters and one nephew manifested secreting PRLoma as the first MEN1 feature at the ages of 19, 15, and 18 years, respectively. A young nephew, genetically diagnosed at the age of 7 years, was still asymptomatic at the time of this study (24 years). The similar inter-familial MEN1 clinical presentation between these two families (even in presence of different mutations and affected gene region) would confirm the anticipation phenomenon of clinical expressivity evidenced in some MEN1 families, and previously described also for familial medullary thyroid carcinoma [13] .
Forty-eight mutated individuals showed no sign and symptoms of MEN1 at the time of the study. The great 4 (9) 3 (21) 2 (32) 1 ( (40) were aged less than 40 years, and 4 were aged 42-46 years; presumably MEN1 has not manifested yet in all these subjects because of their age less than 50. Conversely, four of them were over 60 years of age (60, 68, 68, and 75, respectively); the absence of the disease in these individuals, despite the manifestation of the MEN1 phenotype in other members of the same pedigrees, not only confirmed the high intra-familial variability and penetrance of MEN1 tumorigenesis, but also suggested the possible existence of unknown protective factors, which presumably prevent the somatic loss of the wild type copy of MEN1, and, thus, the development of tumors. In summary, our study tends to confirm the absence of a direct correlation between a specific MEN1 mutation, mutation types and mutated regions of the gene, and the specific clinical presentation and penetrance of MEN1 syndrome, not allowing us to foresee the exact future tumor manifestation on the basis of genetic test results. However, more disrupting mutations (nonsense and splicing-site) appear to be significantly associated with more aggressive NETs.
In addition, our study strengthened the importance of the genetic test for an earlier diagnosis and, possibly, a reduction of morbidity and mortality of the syndrome due to the late recognition of MEN1-tumors and malignant progression. Indeed, all the 19 deceased patients had a late MEN1 diagnosis (a great majority of them were clinically diagnosed with MEN1 before 1998, before the availability of the genetic test), presenting at least two manifestations of the syndrome at the time of diagnosis, and indicating the late diagnosis (and the subsequent late therapeutic interventions) as one of the principal causes of mortality. The introduction of the genetic test was surely a landmark in the diagnosis of MEN1, allowing a significant decrease in lag time of diagnosis between a MEN1 index cases and his/her relatives [13] . During the last twenty years, the genetic test has progressively favored, in association with the constant progression in clinical diagnostic tools, surgery techniques and pharmaceutical therapies, a better management of patients and a subsequent reduced rate of morbidity and mortality [14, 15] . Today, MEN1 tumors in relatives of affected index cases are commonly diagnosed earlier, as a result of a more and more capillary application of the genetic test, an increased disease awareness (i.e., institution of MEN1 referral centers, creation of patients' associations) and a constant progression in diagnostic screening tools. In our series, the genetic testing allowed to identify 48 still asymptomatic carriers, who are, currently, under constant diagnostic screening, according to both the recommended and the suggested clinical, biochemical and imaging screenings of the international clinical practice guidelines for MEN1 [16] .
Finally, data from the analysis of intra-familial MEN1 clinical phenotypes, age of onset, and disease penetrance in our pedigrees further enforced the hypothesis of the role of other genetic and, perhaps, epigenetic, still unknown, modifying factors, in the determination of individual MEN1 tumorigenesis.
